First Pharmaceutical Formulations of Cannabidiol in Development for Multiple Sclerosis

MMJ BioScience is in the developmental stages of the first pharmaceutical formulations of a cannabidiol (CBD) derived from certain cannabis plant extracts. The company is also beginning phase 2 studies to examine the medication in primary progressive multiple sclerosis (PPMS). 
Pharmaceutical CBD is a consistent, standardized formulation of CBD that meets chemical purity and quality measures, according to a press release.
The product is an oral pill consisting of a pharmaceutical formulation of purified THC and CBD. If approved, it will be the first in a new class of MS drugs, as well as the first FDA-approved prescription medication derived from marijuana. 
“Multiple sclerosis is a disease that interferes with your brain’s ability to operate your body and it can be disabling,” said Denis Harris, MD, in a release. “Evidence suggest that the disease happens when your immune system attacks a substance called myelin. The myelin acts as a type of insulation on your nerve cells. This process can lead to damage in and around the nerves in your brain and spinal cord.
“A large percentage of these patients are resistant to currently available treatments and experience multiple symptoms including spasticity and pain. These conditions are difficult to manage and treatment options are currently limited, particularly in PPMS, for which there are currently only 1 FDA-approved treatment. The day-to-day impact of these devastating conditions are significant and, with high rates of mortality.”
The treatment will be studied in large, well-controlled clinical trials aimed at producing high-quality, substantial safety and efficacy data to submit as part of a New Drug Application to the FDA in early 2018.
Scientists at MMJ BioScience are creating a pipeline of clinical-stage cannabinoid candidates for orphan and non-orphan indications that primarily focus on MS neurological conditions, according to the release.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

A new study questions medical marijuana’s role in reducing opioid use.
An HIV primary care program is working to reduce the number of new HIV diagnoses and increase viral suppression rates in Long Island and Queens.
Fingolimod (Gilenya, Novartis) is the first FDA-approved treatment to treat multiple sclerosis in pediatric patients.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.